Literature DB >> 1374868

Selectivity of cholecystokinin (CCK) receptor antagonists, MK-329 and L-365,260, for axonally-transported CCK binding sites on the rat vagus nerve.

J G Mercer1, C B Lawrence.   

Abstract

The ability of the cholecystokinin (CCK) receptor antagonists, MK-329 and L-365,260, to selectively inhibit 125I-Bolton-Hunter-CCK8 binding to ligated rat vagus nerve in vitro was examined at concentrations ranging from 10(-10) M to 10(-6) M. Both antagonists inhibited binding to CCK binding sites accumulating proximal to ligatures on the cervical vagus. Incubation of nerve sections in the presence of both antagonists produced an additive effect, indicating that both CCK-A and CCK-B binding sites are transported towards the periphery. In contrast, CCK binding sites accumulating distal to the ligature possessed the pharmacological characteristics of the CCK-B receptor sub-type only.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374868     DOI: 10.1016/0304-3940(92)90410-9

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

1.  Appetite-Related Gut Peptides in Obesity and Binge Eating Disorder.

Authors:  Allan Geliebter; Christopher N Ochner; Roni Aviram-Friedman
Journal:  Am J Lifestyle Med       Date:  2008-07-01

2.  Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in lean mice.

Authors:  M D Barrachina; V Martínez; L Wang; J Y Wei; Y Taché
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

3.  CCK-A and CCK-B selective receptor agonists and antagonists modulate olfactory recognition in male rats.

Authors:  M Lemaire; G A Böhme; O Piot; B P Roques; J C Blanchard
Journal:  Psychopharmacology (Berl)       Date:  1994-08       Impact factor: 4.530

Review 4.  The gut and food intake: an update for surgeons.

Authors:  E Näslund; P M Hellström; J G Kral
Journal:  J Gastrointest Surg       Date:  2001 Sep-Oct       Impact factor: 3.452

5.  Exogenous cholecystokinin-8 reduces vagal efferent nerve activity in rats through CCK(A) receptors.

Authors:  V Bucinskaite; M Kurosawa; T Lundeberg
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

6.  Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation.

Authors:  L C Stanfa; A H Dickenson
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

7.  Serotonin and cholecystokinin synergistically stimulate rat vagal primary afferent neurones.

Authors:  Y Li; X Y Wu; C Owyang
Journal:  J Physiol       Date:  2004-07-02       Impact factor: 5.182

8.  A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin.

Authors:  R Pietrowsky; A Thiemann; W Kern; H L Fehm; J Born
Journal:  Psychoneuroendocrinology       Date:  1996-08       Impact factor: 4.905

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.